期刊
CLINICAL AND VACCINE IMMUNOLOGY
卷 15, 期 11, 页码 1638-1643出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00167-08
关键词
-
资金
- Wyeth-Lederle, Inc.
- NIH/NIAID [AI030731, AI50132, K24-AI071113, UL1 RR025014]
- GlaxoSmithKline
- Antigenics
- Astellas
- Novartis
- Powdermed
- Aicuris
- Medigene
- Merck Vaccines
- Amgen
We conducted a double-blind, vehicle-controlled, dose escalation safety and immunogenicity trial of a candidate herpes simplex virus type 2 (HSV-2) surface glycoprotein D2 (gD2) DNA vaccine administered by use of a needle-free device. Sixty-two healthy adults were randomized using a 4:1 vaccine-to-placebo ratio. Half of the participants were HSV-1 seronegative, and all were HSV-2 seronegative. Vaccine doses included 100 mu g, 300 mu g, 1,000 mu g or 3,000 mu g of a plasmid expressing the gD2 protein. Subjects received vaccine at 0, 4, 8, and 24 weeks. Some subjects received an additional 1,000-mu g boost at 52 weeks. We found that the vaccine was safe and well tolerated, with most adverse events being local site reactions. No dose-limiting toxicities were observed. gD2-specific cytotoxic T-lymphocyte and lymphoproliferation responses were detected 2 weeks after the third vaccine injection in one of four HSV-1-seronegative, HSV-2-seronegative participants who received 3,000 mu g of vaccine. A DNA-based vaccination strategy against HSV-2 appears to be safe and may generate a vaccine-specific cellular immune response, but high vaccine doses are likely needed to elicit an immune response in most vaccinees.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据